BIO-TECH Systems, Inc. - Report #280: The Market for PET Radiopharmaceuticals & PET Imaging

Market Research in the Healthcare Field with Expertise in Medical Imaging and Radioisotopes

Bio-Tech Systems, Inc. - 4167 West Pinecrest Circle - Las Vegas, Nevada 89121 phone: (702) 456-7608 - fax: (702) 456-2189


	HOME

	ABOUT BIO-TECH SYSTEMS

	AUTHOR'S C.V.

	BREAKING MARKET NEWS

	REPORT #280 The Market for PET Radiopharmaceuticals & PET Imaging New! Released in Jun. 2008!
Report Contents
Partial List of Exhibits

	REPORT #270 The U.S. Market for Diagnostic Radiopharmaceuticals New! Released in Nov. 2007!

	REPORT #260 The U.S. Market for Medical Imaging Contrast Media

	REPORT #230 The World Market for Therapeutic Radiopharmaceuticals

	REPORT #170 The U.S. Market for Brachytherapy Products

	ORDERS

	NEWS RELEASES

	CONTACT US

THE MARKET FOR PET RADIOPHARMACEUTICALS & PET IMAGING

BIO-TECH SYSTEMS INC. announces the publication of:

BIO-TECH Report #280,
The Market for PET Radiopharmaceuticals & PET Imaging

The PET Report Includes:

Present and Emerging Markets for PET Imaging
Analysis of Current and Future FDG Sales
New Prospects for PET Procedures
New Targeted Tracers and Molecular Probes for PET
US and Worldwide Markets for PET Scanners
Growth of Rubidium PET Market for Cardiology
Market Trends Toward High Performance PET-CT Scanners
Continued Rapid Growth in International Sales
Technological Trends and Competitive Challenges
Market Assessment and Sales Forecasts to 2015

The report has a strong focus on new products and technology and emerging market opportunities. The overlap between PET and radiology, which was stimulated by the success of combined PET-CT systems, has allowed radiologists to promote the advantages of multi-modality imaging to both patients and investors in PET imaging facilities. As the availability of PET increases and its capabilities become more visible to referring physicians, it will encourage procedure growth in oncology as well as cardiology and neurology. Recent success of the National Oncologic PET Registry (NOPR) will help expand indications for PET and increase eligibility for reimbursement for many PET providers. New PET radiopharmaceuticals and molecular tracers are also in the pipeline that will measure biochemical processes that show patient response to therapy. This will overcome some of the limitations of conventional FDG-PET and allow measurement of cellular response to therapy rather than metabolism. This will aid in treatment monitoring and therapy planning for breast cancer, prostate cancer, brain cancer, bone cancer, and other common cancers.

GROWTH OF PET PROCEDURE VOLUME AND SALES OF FDG
The demand for PET continued to grow in 2007 reaching 1.8 million procedures, an increase of 21% for the year. Growth should continue with procedure volume increasing 20% in 2008. By 2015, PET procedure volume should rise to 7.1 million procedures. Expanded use of PET in oncology coupled with effective use of the NOPR PET Registry have added substantially to procedure volume. Although the dominant focus of PET is still in oncology, applications in cardiology are increasing, including rubidium PET studies for myocardial perfusion. Myocardial viability studies with PET are also benefiting from fast, multi-slice PET-CT’s suitable for cardiac imaging. PET has also become more accessible to a wider base of physicians and patients, increasing the referral base. This has stimulated sales of FDG, while reducing the cost per dose. FDG sales of $332 million in 2007 will increase 17% in 2008 to $389 million and reach $1,324 million by 2015. These estimates are conservative and are based on present utilization. It is likely that PET reimbursement will eventually be expanded to open coverage, similar to MRI and CT, which will allow wider use of PET procedures.

SALES GROWTH OF PET IMAGING SYSTEMS
In 2007, there were 219 PET scanners ordered domestically including refurbished systems. Internationally, there were 291 PET scanners ordered. Therefore, the worldwide market comprised 510 PET scanners. US bookings were $348.6 million (including refurbs) and international bookings were $513.8 million, with a worldwide total of $862.3 million. Domestic orders were down 19.2% from the previous year. However, international orders increased 9.0%. Nevertheless, worldwide bookings were down 4.4% due to the weakness in the U.S. market. Reduced reimbursement will eventually be offset by more efficient utilization of existing PET scanners based on current growth of procedure volume. Continued use of the NOPR Registry and better education should allow an increase in PET referrals and that will offset equipment and operating costs. By 2015, the U.S. market for PET scanners should reach $690 million and the worldwide market will grow to $1,568 million. The proportion of international sales will continue to increase in the near term. However, over the long term, the ratio of U.S. to worldwide sales will stabilize at about 45% U.S., 55% international. Mobile sales will also recover and comprise about 25% of overall bookings, providing an important underpinning in the PET market.

Please follow one of the links below, or on the left, to find out more information about BIO-TECH Report #280. If you are interested in purchasing BIO-TECH Report #280, please follow this link to our Online Order Form.

To download a detailed Table of Contents (TOC) for BIO-TECH Report #280, please click on one of the two links below. The documents are a Microsoft Word 97-2000 file and an Adobe Acrobat 6 PDF file.

Download TOC in MS Word format (40KB)

Download TOC in Adobe PDF format (25KB)

Report Contents | Partial List of Exhibits

Report #280 Home Page

Download Report #280 Table of Contents:

BTSI280.doc -OR-

BTSI280.pdf

Send this page to a friend